ArticleBiochemical Society transactions2012
Using a bacteriocin structure to engineer a phage lysin that targets Yersinia pestis.
Article in Biochemical Society transactions, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Characterization of LysBM1, a novel high-penetrating phage lysin targeting enterohemorrhagicFrontiers in veterinary science · 2025Article
- What's in a Name? An Overview of the Proliferating Nomenclature in the Field of Phage Lysins.Cells · 2023Review
- PlyKp104, a Novel Phage Lysin for the Treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and Other Gram-Negative ESKAPE Pathogens.Antimicrobial agents and chemotherapy · 2023Article
- Succinyl Chitosan-Colistin Conjugates as Promising Drug Delivery Systems.International journal of molecular sciences · 2022Article
- Future Drug Targets in Periodontal Personalised Medicine-A Narrative Review.Journal of personalized medicine · 2022Review
- P22 Phage Shows Promising Antibacterial Activity under Pathophysiological Conditions.Archives of microbiology & immunology · 2022Article
- Antibiotic Therapy of Plague: A Review.Biomolecules · 2021Review
- Managing urinary tract infections through phage therapy: a novel approach.Folia microbiologica · 2020Review
- The therapeutic potential of bacteriocins as protein antibiotics.Emerging topics in life sciences · 2017Article
- Bacteriophages and Their Immunological Applications against Infectious Threats.Journal of immunology research · 2017Review
- Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii.Antimicrobial agents and chemotherapy · 2016Article
- Novel Engineered Peptides of a Phage Lysin as Effective Antimicrobials against Multidrug-Resistant Acinetobacter baumannii.Antimicrobial agents and chemotherapy · 2016Article
- Antibacterial activity of a lectin-like Burkholderia cenocepacia protein.MicrobiologyOpen · 2013Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Purified phage lysins present an alternative to traditional antibiotics and work by hydrolysing peptidoglycan. Phage lysins have been developed against Gram-positive pathogens such as Bacillus anthracis and Streptococcus pneumoniae, where the peptidoglycan layer is exposed on the cell surface. Addition of the lysin to a bacterial culture results in rapid death of the organism. Gram-negative bacteria are resistant to phage lysins because they contain an outer membrane that protects the peptidoglycan from degradation. We solved crystal structures of a Yersinia pestis outer-membrane protein and the bacteriocin that targets it, which informed engineering of a bacterial-phage hybrid lysin that can be transported across the outer membrane to kill specific Gram-negative bacteria. This work provides a template for engineering phage lysins against a wide variety of bacterial pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.